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Normal lymphocyte development and func-
tion relies on the successful rearrangement and 
modification of antigen receptor genes. Diversity 
of the B cell receptor is largely provided by 
V(D)J recombination where the variable (V), 
diversity (D), and joining (J) segments of the 
immunoglobulin (IG) loci are joined in a combi-
natorial manner (Jung et al., 2006). After antigen 
experience, the IG loci are further modified by 
somatic hypermutation (SHM) and class switch 
recombination (CSR). The recombination- 
activating proteins 1 and 2 (RAG1 and RAG2) 
introduce double-strand breaks (DSBs) at re-
combination signal sequences located around 
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DNA repair mechanisms are fundamental for B cell development, which relies on the so-
matic diversification of the immunoglobulin genes by V(D)J recombination, somatic hyper-
mutation, and class switch recombination. Their failure is postulated to promote genomic 
instability and malignant transformation in B cells. By performing targeted sequencing of 
73 key DNA repair genes in 29 B cell lymphoma samples, somatic and germline mutations 
were identified in various DNA repair pathways, mainly in diffuse large B cell lymphomas 
(DLBCLs). Mutations in mismatch repair genes (EXO1, MSH2, and MSH6) were associated 
with microsatellite instability, increased number of somatic insertions/deletions, and altered 
mutation signatures in tumors. Somatic mutations in nonhomologous end-joining (NHEJ) 
genes (DCLRE1C/ARTEMIS, PRKDC/DNA-PKcs, XRCC5/KU80, and XRCC6/KU70) were identi-
fied in four DLBCL tumors and cytogenetic analyses revealed that translocations involving 
the immunoglobulin-heavy chain locus occurred exclusively in NHEJ-mutated samples. The 
novel mutation targets, CHEK2 and PARP1, were further screened in expanded DLBCL 
cohorts, and somatic as well as novel and rare germline mutations were identified in 8 and 
5% of analyzed tumors, respectively. By correlating defects in a subset of DNA damage 
response and repair genes with genomic instability events in tumors, we propose that these 
genes play a role in DLBCL lymphomagenesis.
© 2013 de Miranda et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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associated, with IG gene diversification processes in a set of 
mature B cell lymphomas, with a focus on DLBCL. The de-
fects in a subset of DDR and repair genes identified here, and 
their association with genomic instability phenotypes, sup-
port their role in the tumorigenesis of DLBCL.
RESULTS
Performance of target enrichment and SOLiD sequencing
73 DDR and repair genes (from this point forward referred to 
as DNA repair genes), belonging to the DDR, BER, nucleotide 
excision repair (NER), MMR, NHEJ, Fanconi anemia (FA), 
and homologous recombination (HR) pathways (Table S1), 
were selectively sequenced in 29 mature B cell lymphomas, 
including 22 DLBCLs, 5 FLs, 2 Burkitt lymphomas (BLs), and 
their respective paired blood samples. As a positive control, the 
TNFAIP3 gene, encoding a known tumor suppressor (A20) 
in DLBCL (Compagno et al., 2009), was also analyzed in 
these samples. Target enrichment was accomplished by the 
Selector technology and samples were sequenced with the 
SOLiD platform. More than 106 SOLiD short-reads were 
generated per sample with >90% of reads being specific for 
the defined regions of interest (ROI; Table S2). Mean se-
quencing depth was >200×, with >84 and 90% of the ROI 
being covered by at least 10 and 5 SOLiD sequencing reads, 
respectively (Table S2). Validation of the sequencing proce-
dure and variant calling methods were performed by process-
ing a HapMap sample (NA19240) in parallel with the clinical 
samples. A concordance of 99.6% was achieved in the 499 
heterozygous positions covered by our Selector design in the 
HapMap sample.
Detection of somatic and germline mutations  
in DNA repair genes
To detect germline as well as somatic mutations, sequences 
from both normal and tumor samples were compared with 
the human genome reference (hg18), and subsequently, minor 
allele frequencies (MAFs) at heterozygous positions were 
compared between tumor and normal pairs. Filtering of 
known polymorphisms was performed against dbSNP132 
and variant novelty verified with dbSNP137. By combining 
both analysis and removing overlapping results, 442 single 
nucleotide variants (SNVs) were identified across all samples. 
Approximately half of these variants passed visual inspection, 
which allowed the elimination of false positive results derived 
from library preparation, sequencing, and/or alignment artifacts 
(Fig. S1). Such artifacts were normally located toward the end 
of the sequencing reads or were variants supported by iden-
tical sequencing reads. 124 heterozygous SNVs resulted in 
nonsynonymous amino acid changes that included novel 
germline and somatic mutations as well as rare germline vari-
ants with an MAF below 0.01 (Fig. S1). All novel germline 
and somatic mutations and rare variants were validated by 
Sanger sequencing and are presented in Table S3. Detection 
of indels proved to be difficult, and an alternative alignment 
of SOLiD short-reads was produced with BFAST that allowed 
the identification of four somatic deletions in four different 
the V, D, and J genes during V(D)J recombination, whereas 
activation-induced cytidine deaminase (AID) initiates SHM 
and CSR by deaminating cytosines to uracils at the V and 
switch (S) regions of the IG loci (Jung et al., 2006; Di Noia 
and Neuberger, 2007).
A myriad of DNA damage response (DDR) and repair 
proteins mediate and regulate IG diversification processes. 
AID activity provokes guanosine/uracil mismatches that are 
processed by proteins of the base-excision repair (BER) path-
way (UNG, APEX1) and mismatch repair (MMR) pathway 
(MSH2/MSH6, MLH1/PMS2, and EXO1; Di Noia and 
Neuberger, 2007; Stavnezer et al., 2010). While in the context 
of CSR such mismatches lead to the generation of DNA 
DSBs, during SHM, AID activity preferentially results in the 
establishment of point mutations, although small duplications 
and deletions may also occur. The resolution of DSBs in V(D)J 
recombination and CSR is primarily mediated by the non-
homologous end-joining (NHEJ) pathway that becomes acti-
vated by DDR proteins such as ATM and Nibrin (NBN; 
Kotnis et al., 2009). The x-ray repair cross-complementing 
proteins 4 (XRCC4), XRCC5 (Ku80), and XRCC6 (Ku70) 
and DNA ligase 4, Artemis, DNA-PKcs, and Cernunnos (XLF) 
proteins are considered to be the core members of NHEJ 
(Lieber, 2010).
Most B cell neoplasms are thought to originate from 
antigen-experienced B cells, as tumor cells display SHM at the 
IG V genes (Klein and Dalla-Favera, 2008). Furthermore, a 
role for IG diversification mechanisms in the propagation of 
genomic instability in mature B cell lymphomas is supported 
by numerous observations. Non-IG genes, including proto-
oncogenes such as MYC, BCL6, PIM1, RHOH, or PAX5 are 
often targeted by SHM, especially in diffuse large B cell lym-
phomas (DLBCLs; Pasqualucci et al., 2001), one of the most 
common and aggressive mature B cell lymphoma subtypes. 
Chromosomal translocations involving the IG loci, with break-
points in S regions and SHM targets, are also a hallmark of 
mature B cell lymphomas (Küppers and Dalla-Favera, 2001; 
Lenz et al., 2007). Furthermore, AID has been shown to be 
essential for the occurrence of c-myc/IgH translocations and 
oncogene-driven induction of germinal center–derived lym-
phomas in mice (Ramiro et al., 2004; Pasqualucci et al., 2008). 
Of note, the t(14;18) translocation, involving the IGH and 
the BCL2 loci, characteristic of follicular lymphomas (FLs), is 
considered to be derived from defective V(D)J recombination 
processes (Küppers and Dalla-Favera, 2001).
Despite the crucial role of DDR and repair proteins dur-
ing antibody diversification processes, there is lack of evidence 
that supports their direct involvement in the propagation of 
genomic instability in human B cell lymphomas. In contrast, 
individuals with biallelic germline mutations in some of 
the DNA repair genes that encode proteins involved in IG 
diversification processes often display an increased risk for 
development of lymphoid malignancies in addition to immuno-
deficiency (de Miranda et al., 2011). In this study, we sys-
tematically analyzed the coding regions of key DDR and 
repair genes that have been associated, or could potentially be 
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and EXO1 which were represented by <20% of sequencing 
reads (Table 1). The low percentage of sequencing reads that 
supported the deletions at the DCLRE1C and PARP1 genes 
probably resulted from the problematic alignment of SOLiD 
reads with deletions of five or more nucleotides. Nevertheless, 
these deletions were readily validated by Sanger sequencing 
and are likely to be present in dominant tumor cell clones in 
a heterozygous state.
The mean frequency of nonsynonymous, somatic muta-
tions in DNA repair genes was 4.16 mutations/Mb of target 
sequence (protein coding). To compare the mutation frequen-
cies in DNA repair genes with the ones found in the entire 
coding genome (exome), we performed exome sequencing 
in 17 out of the 22 DLBCL cases that underwent Selector/
SOLiD sequencing. Although biases could arise from the use 
of different techniques, the somatic mutations in DNA repair 
genes discovered by exome sequencing largely overlapped 
with the ones detected by Selector/SOLiD and translated 
into a mutation frequency of 4.21 mutations/Mb. This fre-
quency was similar to the ones determined for the entire cod-
ing genome (3.15 mutations/Mb, 20,930 genes) and for 
specific groups of genes such as kinases (3.71 mutations/Mb, 
507 genes) or transcription factor genes (3.44 mutations/Mb, 
1,645 genes). Of note, the latter gene groups encompass fre-
quent mutation targets in DLBCL such as PIM1 (kinase) or 
BCL6 and TP53 (transcription factors). After excluding mu-
tations in the classical tumor suppressor TP53, the somatic 
mutation frequency in DNA repair genes detected by exome 
was reduced (3.01 mutations/Mb) but remained comparable 
to the ones derived from the entire coding genome and other 
gene groups.
genes across three independent tumors. All nonsynonymous 
somatic mutations were detected exclusively in DLBCL cases 
(Table S3). No somatic mutations were found in FL and BL 
samples despite comparable sequencing performances.
DNA repair pathways targeted by mutations in DLBCL
19 somatic mutations were discovered by SOLiD sequenc-
ing, distributed in 10 DLBCL tumors (Table 1 and Table S3). 
These were more frequent in DDR factors, including the 
classical tumor suppressor genes ATM and TP53, and the 
CHEK2 and PARP1 genes that are novel mutation targets 
in DLBCL. Recurrent alterations in MMR genes (EXO1, 
MSH2, and MSH6) and members of the NHEJ pathway 
(DCLRE1C/ARTEMIS, PRKDC/DNA-PKcs, XRCC5/
KU80, and XRCC6/KU70) were also observed (Fig. 1 and 
Table 1). Additionally, two somatic mutations were found 
in BRCA2 (HR pathway) and one mutation in the DDB1 
(NER pathway) and TNFAIP3 genes (Table 1). To the best of 
our knowledge, and as observed for CHEK2 and PARP1, 
nonsynonymous somatic mutations in DCLRE1C, EXO1, and 
XRCC5 have not been previously reported in DLBCL. The 
somatic mutations discovered in the DCLRE1C, PARP1, 
XRCC6, and TNFAIP3 genes were frameshift deletions, whereas 
the remaining somatic mutations led to amino acid substitu-
tions (Table 1). The SIFT and Polyphen-2 prediction tools 
provided a discordant functional prediction for five missense 
mutations (Table 1), which may be due to the use of different 
algorithms and sequence alignments (Hicks et al., 2011).
Based on the percentage of sequencing reads, the majority 
of somatic mutations were considered to be present in domi-
nant tumor cell clones, except for the ones targeting ATM 
Table 1. Somatic mutations discovered by targeted SOLiD sequencing
Gene Base change AA change Percentage of sequencing reads SIFT Polyphen
%
ATM c.3616T>G p.L1206V 10 Tolerated Benign
ATM c.3646T>C p.Y1216H 12 Tolerated Damaging (probably)
BRCA2 c.2546T>C p.V849A 33 Tolerated Benign
BRCA2 c.9966G>T p.M3322I 36 Tolerated Damaging (probably)
CHEK2 c.1007A>T p.Q336L 54 Damaging Benign
DCLRE1C c.1628_1632delTAACA p.(I543Rfs*12) 10 - -
DDB1 c.26C>G p.A9G 86 Damaging Damaging (possibly)
EXO1 c.1412A>G p.K471R 18 Tolerated Benign
MSH2 c.1618A>G p.S540G 20 Tolerated Benign
MSH2 c.2497C>G p.L833V 50 Damaging Benign
MSH6 c.1628A>G p.K543R 29 Damaging Benign
PARP1 c.1910_1922delinsGTT p.(K637Sfs*13) 18 - -
PRKDC c.10252T>C p.F3418L 31 Damaging Damaging (probably)
TNFAIP3 c.1877_1878delTG p.(C627Ffs*44) 20 - -
TP53 c.400T>G p.F134V 47 Damaging Damaging (probably)
TP53 c.817C>T p.R273C 67 Damaging Damaging (probably)
TP53 c.818G>A p.R273H 38 Damaging Damaging (probably)
XRCC5 c.847A>G p.T283A 29 Damaging Damaging (probably)
XRCC6 c.800delT p.(I267Kfs*2) 28 - -
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were rare in HR and FA proteins, several germline mutations 
were identified in these pathways. Alterations in genes func-
tionally related to the DDR pathway were also common. One 
DLBCL and two FL patients carried novel germline mutations 
in the MDC1 gene that encodes a core DDR protein. 21 rare 
variants (with MAF < 0.01) were identified in 17 mature B cell 
lymphoma patients. Of note, four patients (three DLBCL and 
one FL) carried rare nonsynonymous substitutions in the gene 
encoding TP53BP1, another essential DDR protein (Table S3).
19 mature B cell lymphoma patients carried novel non-
synonymous germline mutations in different DNA repair 
genes (Table S3). These were more frequent in members of the 
MMR pathway (Fig. 1). Three mutations were identified in the 
MSH3 gene, whereas two mutations were detected in the MLH3 
gene in four DLBCL patients (Table S3). Furthermore, nonsyn-
onymous germline mutations in MSH6, PMS1, and PMS2 were 
also identified in DLBCL patients, whereas one FL patient car-
ried a novel mutation in MSH2. Although somatic mutations 
Figure 1. DNA repair pathways affected by somatic 
and novel germline mutations in DLBCL. Somatic and 
novel germline mutations together were most frequent 
in MMR genes, followed by general DDR genes and NHEJ 
genes. To a lower extent, mutations were detected in FA, 
HR, BER, and NER pathways. The “Other” category refers 
to the p.R335W mutation in the DNTT gene, which en-
codes for a protein involved in the addition of nucleo-
tides at junctions of rearranged IGH and TCR gene 
segments during V(D)J recombination. The percentage of 
DLBCL tumors affected by somatic or novel germline 
mutations in different DNA repair pathways is displayed. 
Mutations were discovered by SOLiD and validated by 
Sanger sequencing.
Table 2. Summary of variations discovered in CHEK2 in an expanded DLBCL cohort (n = 235)
DNA Protein Novel/SNP Mutated 
tumors
Somatic/germline Ethnic 
origin
MAF 
controls‡
MAF 1000 
genomes§
SIFT Polyphen
c.319+2T>A - Novel 1/171 ND Swedish 0 0 - -
c.876dupT p.D293X Novel 1/171 Somatic Swedish 0 0 - -
c.1007A>T p.Q336L Novel 1/64 Somatic Chinese 0 0 Damaging Damaging 
(possibly)
c.1091T>C p.I364T Novel 1/171 ND Swedish 0 0 Damaging Damaging 
(probably)
c.7C>T p.R3W rs199708878 1/171 Germline Swedish 0 0 Damaging Damaging 
(probably)
c.349A>G p.R117G rs28909982 1/171 ND Swedish 0 0 Damaging Damaging 
(probably)
c.444+1G>A - Reported 1/171 Germline Swedish 0 0 - -
c.1312G>T p.D438Y rs200050883 2/164 ND Swedish 0 0 Damaging Damaging 
(probably)
c.1582G>A p.E528K rs138040612 1/64 Germline Chinese 0 0 Tolerated Damaging 
(possibly)
c.470T>C p.I157T rs17879961 3/171 Germline (1) Swedish 0.008 0.007 Tolerated Damaging 
(possibly)
c.538C>T p.R180C rs77130927 1/171 ND Swedish 0.006 0.001 Damaging Damaging 
(possibly)
c.1100delC p.T367Mfs*15 Reported 3/163 ND Swedish 0.006 0 - -
c.1111C>T p.H371Y Reported 2/64 Somatic/germline Chinese 0.004 0 Damaging Benign
The expanded DLBCL cohort was comprised of 171 Swedish and 64 Chinese cases. Population-specific MAFs for MAF controls were calculated by typing 1,030 Swedish or 429 
Chinese controls, with an exception for p.D438Y, p.E528K, and c.1100delC variants, which were screened by Sanger in 703, 361, and 345 controls, respectively. For MAF, data 
from 1,000 genomes were available for 379 European and 197 Chinese controls. ND, not determined. (1), germline origin was confirmed in one patient.
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including p.E528K, were specific for the patient cohort, as 
they were not identified in large groups of controls (Table 2). 
Of these, the c.444+1G>A splice site mutation has been 
previously reported to lead to aberrant splicing of CHEK2 
transcripts, whereas the p.R117G and p.D438Y substitu-
tions were shown to have deleterious effects on the function 
of CHEK2 (Sodha et al., 2006; Bell et al., 2007). Four other 
rare variants were found in both tumor and control samples, 
including a c.1100delC deletion and a p.I157T substitution 
(Table 2) that was previously shown to have a damaging 
effect on protein function (Falck et al., 2001). Sequencing of 
the entire coding regions of the CHEK2 gene was also per-
formed in 90 samples derived from healthy blood donors, 
where the p.R180C and p.I157T substitutions, previously 
identified by genotyping, were the only variants found 
in one and two samples, respectively. Thus, the discovery of 
novel mutations or certain rare variations was restricted to 
the DLBCL patient group, further suggesting their associa-
tion with the disease.
Screening of mutation targets  
in expanded cohorts of DLBCL tumors
Six mutated genes discovered by SOLiD sequencing were 
selected for further investigation in an extended cohort of 
DLBCL tumors. These include CHEK2, PARP1, DDB1, and 
XRCC5, which were novel mutation targets for DLBCL, and 
MSH2 and MLH3, which were recurrently affected by so-
matic and/or germline mutations, respectively.
The CHEK2 gene was Sanger sequenced in a total of 
235 DLBCL samples, including the 22 DLBCL samples that 
underwent targeted SOLiD sequencing. In addition to the 
p.Q336L somatic mutation and the p.E528K germline vari-
ant, identified by SOLiD, 11 novel mutations and previously 
reported rare variants were detected, distributed in 17 tu-
mors that did not undergo SOLID sequencing (Table 2). 
The novel mutations identified in CHEK2 included a so-
matic frameshift insertion (p.D293X), a splice-site mutation 
(c.319+2T>A), and a missense mutation (p.I364T) located 
in the kinase domain of CHEK2 (Table 2). Five rare variants, 
Table 3. Summary of variations discovered in PARP1, MSH2, DDB1, DCLRE1C, MLH3, and XRCC5 after sequencing of expanded 
DLBCL cohorts
Gene DNA Protein Method Novel/SNP Somatic/ 
germline
Ethnic 
origin
MAF 1,000 
genomes‡
SIFT Polyphen
PARP1 c.1897A>T p.K633X Sanger Novel Somatic Chinese 0 - -
c.1910_1922delinsGTT p.(K637Sfs*13) Selector & 
Sanger
Novel Somatic Chinese 0 - -
c.2326A>G p.S776G Selector & 
Sanger
Novel Germline Chinese 0 Damaging Damaging (possibly)
c.2756T>C p.I919T Sanger Novel ND Chinese 0 Damaging Damaging (possibly)
c.2789A>G p.Y930C Sanger rs189410139 ND Chinese 0.003 Damaging Damaging (probably)
c.3037C>A p.L1013M Sanger rs138906127 ND Swedish 0.001 Tolerated Damaging (possibly)
MSH2 c.1316C>T p.P439L Sanger Novel ND Chinese 0 Damaging Damaging (probably)
c.1619A>G p.S540G Selector & 
Sanger
Novel Somatic Chinese 0 Tolerated Benign
c.2498C>G p.L833V Selector & 
Sanger
Novel Somatic Chinese 0 Damaging Benign
c.505A>G p.I169V Sanger rs63750716 ND Chinese 0 Tolerated Benign
DDB1 c.26C>G p.A9G Selector Novel Somatic Chinese 0 Damaging Damaging (probably)
c.2375_2376dupTT p.(I793Lfs*75) 454 amplicon Novel ND Chinese 0 - -
c.3360G>A p.M1120I 454 amplicon Novel ND Swedish 0 Tolerated Benign
DCLRE1C c.536G>A p.R179Q 454 amplicon rs150854849 ND Swedish 0 Damaging Damaging (probably)
c.1628_1632delTAACA p.(I543Rfs*12) Selector Novel Somatic Chinese 0 - -
MLH3 c.119G>A p.C40Y Selector Novel Germline Chinese 0 Damaging Damaging (probably)
c.365A>G p.K122R 454 amplicon Novel ND Chinese 0 Damaging Damaging (probably)
c.2221G>T p.V741I 454 amplicon rs28756990 ND Swedish 0.004 Tolerated Damaging (possibly)
c.2837C>T p.S946F Selector rs201441389 Germline Chinese 0.003 Tolerated Damaging (possibly)
c.2964C>G p.I988M Selector Novel Germline Chinese 0 Damaging Benign
c.3331C>T p.L1111F Selector Novel Germline Chinese 0 Damaging Damaging (probably)
XRCC5 c.847A>G p.T283A Selector Novel Somatic Chinese 0 Damaging Damaging (probably)
c.1046C>A p.S349Y 454 amplicon Novel Germline Chinese 0 Damaging Damaging (probably)
c.1522A>G p.I508V 454 amplicon rs2287558 ND Swedish 0.003 Tolerated Benign
For expanded DLBCL cohort, PARP1 and MSH2 genes were analyzed in 130 (95 Chinese and 35 Swedish) and 94 (59 Chinese and 35 Swedish) DLBCL samples, respectively, 
whereas DDB1, DCLRE1C, MLH3, and XRCC5 genes were sequenced in 48 (25 Chinese and 23 Swedish) DLBCL samples. MAF 1,000 genomes data were available for 379 
European and 197 Chinese controls. ND, not determined.
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a novel missense mutation (p.P439L) and a rare variant 
(p.I169V; Table 3).
The screening of DCLRE1C, DDB1, MLH3, and XRCC5 
genes in 48 DLBCL samples that did not undergo SOLiD 
sequencing was performed in a high-throughput manner by 
combining all PCR reactions in a microfluidic PCR array 
followed by 454 GS FLX Titanium sequencing. Two novel 
mutations were identified in the DDB1 gene, in two different 
tumors, including a frameshift, truncating mutation in DDB1 
(Table 3). The MLH3 and XRCC5 genes also presented one 
novel mutation each in two additional samples (Table 3). Finally, 
rare missense variants were identified in DCLRE1C, MLH3, 
and XRCC5 in three tumors, respectively. The MLH3 missense 
rare variant (p.V741I) was previously shown to segregate with 
disease in an endometrial cancer family (Liu et al., 2003).
Sanger sequencing of the PARP1 gene in 130 DLBCL 
samples, including the tumors that underwent SOLiD se-
quencing, allowed the discovery of two additional novel 
nonsynonymous mutations: a STOP-gain mutation located 
upstream of the catalytic domain of the PARP1 protein 
(p.K633X) and a p.I919T substitution located in the cata-
lytic domain of PARP1 (Table 3). Two rare variants (p.Y930C 
and p.L1013M) were also identified in two different tumors. 
Overall, variations in the PARP1 gene were identified in 
5% of samples analyzed.
The MSH2 gene was also Sanger sequenced in 94 DLBCL 
tumors, including the samples that underwent SOLiD se-
quencing. In addition to the two somatic mutations (p.S540G 
and p.L833V) discovered by the latter approach, another two 
nonsynonymous variants were found in two tumor samples: 
Figure 2. Allelic imbalance at PARP1, EXO1, MDC1, and RPA1 loci in DLBCL samples and association with PARP1 expression. (A) Allelic im-
balance events detected by SOLiD were validated by the use of polymorphic markers and fragment analysis in 22 DLBCL samples. Six additional samples 
that did not undergo SOLiD sequencing were also investigated. Some markers were not informative, because of either germline homozygosity or MSI in 
the tumor samples. Markers displaying allelic imbalance were analyzed in two independent experiments. (B) Expression of PARP1 and EXO1 was deter-
mined by quantitative real-time PCR in samples with and without allelic imbalance at the respective loci. Medians are depicted and the statistical differ-
ence between groups was assessed with the Mann-Whitney test (**, P < 0.01). Two independent experiments were performed and a representative 
experiment is shown.
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differences in terms of gene expression were observed for the 
other loci, indicating that allelic imbalance did not correlate with 
gene copy numbers or that the loss of one allele could be com-
pensated at the transcriptional level (Guidi et al., 2004).
Microsatellite instability (MSI) and mutation profiles  
in MMR-mutated DLBCL
To investigate whether defects in MMR genes translated into 
a particular form of genetic instability, MSI analysis was per-
formed in 28 DLBCL cases for which paired normal samples 
were available, including the 22 DLBCL cases that under-
went targeted sequencing. Two mononucleotide (BAT-25 
and BAT-26) and two dinucleotide (D10S197 and D2S123) 
microsatellite markers were used (Fig. 3 A). Instability in one 
or two markers was detected in five DLBCL samples and was 
almost exclusively restricted to dinucleotide markers. No-
tably, all samples that displayed instability of microsatellites 
possessed at least one alteration in an MMR gene (Fig. 3 B). 
They included the tumor samples DL-30 and DL-48, where 
somatic mutations in MSH6, MSH2, and EXO1 genes were 
discovered by SOLiD sequencing, and one sample (DL-42) 
derived from a DLBCL patient that carried a novel germ-
line mutation in MSH3. Two additional samples (DL-29 and 
DL-57) that displayed instability at microsatellites markers did 
not undergo the current sequencing approach, but have been 
analyzed by whole-exome sequencing–presented somatic 
mutations in PMS1 (p.R847K) and MLH1 (p.A223D), re-
spectively. The DLBCL sample with a p.P439L mutation in 
MSH2 was analyzed with Promega’s MSI analysis system due 
to the lack of paired normal DNA and presented instability of 
one (NR-21) out of the five mononucleotide markers.
Detection of allelic imbalance at DNA repair genes loci
Chromosomal alterations could be detected from the data 
generated by the targeted deep sequencing of DNA repair 
genes. For that purpose we compared allelic ratios at germline 
heterozygous SNVs, between tumor and normal samples. The 
EXO1 locus was found to be affected by allelic imbalance in 
six DLBCL tumors, whereas allelic imbalance at the PARP1 
and RPA1 loci was detected in three DLBCL samples. The 
TP53BP1, ERCC6, and ATR genes were affected in two 
samples each and other loci were affected in single DLBCL 
samples, including the MDC1 locus.
The allelic imbalance results obtained from SOLiD se-
quencing were validated by making use of polymorphic 
markers located around the EXO1, PARP1, MDC1, and 
RPA1 loci, and the analysis was extended to a total of 28 
DLBCL samples. The majority of results obtained from SOLiD 
could be confirmed by the employment of polymorphic 
markers except for one case: EXO1 in DL-40 (Fig. 2 A). 
Furthermore, this approach allowed the identification of 
additional samples affected by allelic imbalance that were not 
detected by SOLiD data analysis (Fig. 2 A). This can be ex-
plained by the fact that the detection of allelic imbalance by 
the latter required the presence of at least two germline het-
erozygous SNVs at different loci, which was not always ob-
served. In total, allelic imbalance at RPA1, EXO1, MDC1, 
and PARP1 was detected in 25, 21, 18, and 14% of samples, 
respectively. We subsequently assessed the expression of RPA1, 
EXO1, MDC1, and PARP1 and found that the expression of the 
latter was significantly lower in tumors presenting allelic imbal-
ance (Fig. 2 B). This association might reflect the loss of PARP1 
copy number in samples with allelic imbalance. No significant 
Figure 3. MSI and mutation profiles in MMR-mutated DLBCL. (A) Fragment analysis was performed with microsatellite markers in 28 DLBCL tu-
mors. (B) MSI detection in five DLBCL cases with mutations in MMR genes. MSI detection was confirmed by one independent experiment. (C) The median 
of the total number of somatic mutations in the coding genome (exome) was higher in MMR-mutated DLBCL tumors that displayed MSI than in MSS 
tumors. (D) This difference was significant when looking specifically at the number of somatic indels detected by exome sequencing. (E and F) C:G→A:T 
transversions were significantly enriched in MMR-mutated DLBCL samples displaying MSI. The statistical difference between groups was assessed with 
the Mann-Whitney test (*, P < 0.05).
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break-apart probes in 13 DLBCL cases for which tissue sec-
tions were available, including 3 NHEJ mutants (DL-43, 
XRCC5; DL-48, DCLRE1C; DL-53, XRCC6). A split signal 
affecting one of the IGH loci was detected in 2 out of the 13 
DLBCL cases that were investigated by FISH (Fig. 4 A). This 
abnormality was found in approximately half of the nuclei 
analyzed in each tumor. Remarkably, the two cases where the 
IGH locus was rearranged carried somatic mutations in NHEJ 
genes: DL-43 (XRCC5 mutant) and DL-48 (DCLRE1C 
mutant). No chromosomal breakage at the IGH locus was 
detected in the 10 DLBCL samples that contained unmutated 
NHEJ genes. In spite of the small sample size, the occurrence 
of IGH translocations was significantly different between 
NHEJ mutants and nonmutants as determined by Fisher’s 
exact test (P = 0.04). The DL-43 and DL-48 samples also dis-
played chromosomal breakage at the BCL6 locus (Fig. 4 B) 
but no rearrangement of IGH together with BCL2 or rear-
rangement of the MYC locus (Fig. 4, C and D). We therefore 
concluded that BCL6 was the most likely translocation part-
ner of IGH in these tumors. Disruption of the BCL6 locus, 
without concurrent rearrangement of the IGH locus, was de-
tected in the microsatellite unstable DLBCL DL-42 that carried 
a somatic mutation in TP53 and a novel germline mutation 
in MSH3.
DISCUSSION
By performing targeted screening of 73 DNA repair genes in 
a cohort of mature B cell lymphomas, we discovered somatic 
alterations in several novel and/or potentially functional im-
portant mutation targets in DLBCL, including CHEK2, 
PARP1, DDB1, and several NHEJ genes (DLRE1C, PRKDC, 
XRCC5, and XRCC6), as well as MMR genes (MSH2, MSH6, 
and EXO1). Although the somatic mutation frequency in the 
73 DNA repair gene group was not significantly higher than 
To investigate whether defects in MMR genes were 
associated to the mutational load or mutation signatures 
in DLBCL, whole exome sequencing data were analyzed in 
the five DLBCL cases in which MSI was detected, in four-
teen microsatellite stable (MSS) DLBCL tumors, and in the 
respective paired blood samples. The total number of somatic 
mutations detected by exome sequencing was higher in 
MMR-mutated cases displaying instability of microsatellite 
markers than in MSS tumors, not reaching but rather close 
to statistical significance (Mann-Whitney P = 0.05, Fig. 3 C). 
Interestingly, the number of indels was significantly higher 
in cases with MSI than in MSS tumors (Mann-Whitney P = 
0.02, Fig. 3 D). This observation suggests that MMR defects 
in these tumors not only translate into MSI in noncoding re-
gions but also in the occurrence of insertions and deletions 
within protein-coding exons. Notably, three out of the four 
deletions identified by targeted sequencing of DNA repair 
genes occurred in MMR-mutated DLBCL samples display-
ing MSI. We further investigated whether MMR deficiency 
was associated with different mutation signatures by compar-
ing the type of mutations observed in MMR-mutated cases 
displaying MSI with the ones in MSS tumors. Although C:
G→T:A transitions were dominant in both groups (Fig. 3 E), 
MSI-positive DLBCL tumors were significantly enriched 
with C:G→A:T transversions (Fig. 3 F).
Defects in NHEJ genes and chromosomal  
translocations in DLBCL
Somatic mutations in NHEJ genes were detected in 4 out of 
the 22 DLBCL cases that underwent targeted sequencing of 
DNA repair genes. We further investigated whether muta-
tions in NHEJ genes were associated with genomic instability 
affecting the IGH locus. To this end, we performed fluorescent 
in situ hybridization (FISH) with IGH and BCL6 dual-color 
Figure 4. FISH analysis in DLBCL tumors. The integrity of the IGH and BCL6 loci was assessed by FISH in 13 DLBCL tumors that underwent targeted 
sequencing of DDR and repair genes. Results from DL43 are depicted. (A) Rearrangement of one IGH locus was detected in two DLBCL cases (DL43 and 
DL48), both of which carried a mutation in a NHEJ gene (green, IGHV probe; red, IGH 3 flanking probe). (B) Rearrangement of one BCL6 locus was de-
tected in three tumors, including the two cases that displayed disruption of the IGH locus (green, BCL6 3 flanking probe; red, BCL6 5 flanking probe).  
(C and D) Both cases that displayed concurrent rearrangement of the IGH and BCL6 loci were investigated with an IGH/BCL2 dual fusion translocation 
probe and a MYC break-apart probe to determine the translocation partner of IGH. No fusion signal between IGH and BCL2 probes (C) or rearrangement 
of the MYC locus (D) was observed, thus supporting BCL6 as the most likely translocation partner of IGH in those tumors. The three signals detected by 
the IGH probe (green) of the IGH/BCL2 probe set (C) are consistent with the IGH rearrangement observed using the break-apart probe. Within each ex-
periment, at least 100 intact, nonoverlapping nuclei were scored for each probe, and representative results are depicted.
 o
n
 M
arch 12, 2014
jem.rupress.org
D
ow
nloaded from
 
Published August 19, 2013
JEM Vol. 210, No. 9 
Article
1737
that it preferentially joins DSBs arising within the same 
chromosome (Boboila et al., 2010). The joining of inter-
chromosomal breaks is thought to be instead mediated by a 
microhomology-based alternative end-joining (A-EJ) pathway 
(Boboila et al., 2012). Somatic defects in C-NHEJ compo-
nents, which would provide a genetic basis for the occurrence 
of IG-associated translocations, have been rarely reported 
in human lymphomas. We previously described a somatic 
heterozygous mutation in the NHEJ1 gene, encoding the 
Cernunnos/XLF protein in a DLBCL tumor (Du et al., 2012). 
This tumor sample presented concurrent translocations of 
BCL2 and MYC with both IGH alleles, suggesting a rela-
tion between an NHEJ defect and the occurrence of IGH- 
associated genomic instability. We provide here further support 
for an association between somatic alterations in NHEJ genes 
(DCLRE1C and XRCC5) and the occurrence of genomic 
instability events involving the IGH locus.
The NHEJ pathway, in response to DNA DSB, is highly 
dependent on general damage response mechanisms. DDR 
proteins such as ATM, TP53BP1, and NBN are known to co-
operate with NHEJ factors during V(D)J recombination and 
CSR (Kotnis et al., 2009; Lieber, 2010). In the current work, 
we discovered several novel mutations and rare variants in 
DDR genes, including CHEK2 and PARP1, which are novel 
mutation targets in DLBCL. Certain germline variants in 
CHEK2 are known to confer susceptibility to cancer, particu-
larly of breast and prostate origin, whereas somatic alterations 
are rarely observed in this gene (Antoni et al., 2007). CHEK2 
is a downstream effector of ATM and responsible for convey-
ing DDR signals to substrates involved in cell cycle progres-
sion and apoptosis such as the TP53 tumor suppressor and 
the CDC25 phosphatase family (Ahn et al., 2004). Therefore, 
CHEK2 defects might foster the accumulation of DNA dam-
age during lymphomagenesis by impairing cell cycle check-
points and apoptotic responses. Interestingly, CHEK2 was 
previously shown to be activated by the DNA-PKcs and to be 
associated with the XRCC5/Ku80 and XRCC6/Ku70 pro-
teins (Li and Stern, 2005). Its potential role during the dam-
age response to DNA DSBs during V(D)J recombination and 
CSR requires further investigation.
We found the PARP1 gene to be targeted by different 
mechanisms that included mutations and allelic imbalance. 
PARP1 is involved the initial phases of DDR by accumu-
lating at sites of damage, inducing chromatin remodeling 
and attracting DNA repair factors through the synthesis of 
poly(ADP-ribose) groups (Krishnakumar and Kraus, 2010). It 
has also been suggested to be a component of the A-EJ path-
way (Audebert et al., 2004), particularly during CSR (Robert 
et al., 2009). High PARP1 activity, in response to severe DNA 
damage, was shown to induce cell death, most likely through 
energy depletion (Krishnakumar and Kraus, 2010). The tar-
geting of PARP1 by some DLBCL tumors might, thus, 
constitute a survival adaptation to high degrees of genomic 
instability in B cells. The essential role of PARP1 in HR- 
deficient (BRCA2 deficient) cells has, however, stimulated the 
development of PARP-targeted therapies (Bryant et al., 2005). 
the ones derived from the entire coding genome or from 
other cancer gene–containing gene sets, such as kinases and 
transcription factors, altogether, somatic mutations in DNA 
repair genes affected approximately half of DLBCL cases ana-
lyzed. Furthermore, we have provided evidence that muta-
tions in subsets of these genes, especially those belonging to 
the MMR and NHEJ pathways, indeed associated with dif-
ferent forms of genetic instability in the tumors.
Mutations in MMR genes were associated with an MSI 
phenotype in DLBCL, which is a characteristic form of 
genetic instability in MMR-deficient tumors (Jiricny, 2006). 
Furthermore, these tumors displayed an overall increase of 
somatic mutations throughout the coding genome and of 
small insertions and deletions in particular. In the context 
of B cell development, the MMR system is involved in the 
mutagenic processing of mismatches introduced by AID dur-
ing SHM and CSR (Martin et al., 2003; Bardwell et al., 2004; 
Martomo et al., 2004; Di Noia and Neuberger, 2007). Out-
side the IG locus, the MMR proteins assure a high-fidelity 
postreplicative DNA repair but also protect the genome from 
the off-target activity of AID (Jiricny, 2006; Liu et al., 2008). 
The distinct roles of the MMR system in SHM and postrep-
licative repair are largely unknown but might be explained, at 
least partially, by the involvement of different polymerases 
during these processes (Di Noia and Neuberger, 2007). The 
MSI and mutator phenotypes of the MMR-mutated DLBCL 
cases presented here might derive from both postreplicative 
MMR deficiency and inefficient repair of off-target AID 
activity. Higher mutation loads in MMR-mutated tumors, as 
well as the specific increase of small insertions and deletions, 
have been previously described in human cancers such as 
colorectal (Cancer Genome Atlas Network, 2012) or gastric 
(Nagarajan et al., 2012) cancers but never in DLBCL. The 
increased observation of small insertions and deletions is par-
ticularly relevant as a result of the deleterious consequences of 
these mutations. Similarly, to the best of our knowledge, MSI 
phenotypes were not previously associated with somatic mu-
tations in MMR in DLBCL. Interestingly, we discovered that 
C:G→A:T transversions were relatively more frequent in 
MMR-mutated DLBCLs with MSI. The relative increase in 
C:G→A:T transversions, in the context of MMR deficiency, 
has been previously reported for mutL and mutS E. coli mu-
tants (Zhao and Winkler, 2000) and in Msh2 heterozygous 
mutant mice exposed to PhIP, a food-borne carcinogen 
which induces a C:G→A:T mutation signature (Zhang et al., 
2001). The fact that MMR defects correlated with charac-
teristic mutagenic signatures supports a role for MMR in 
DLBCL lymphomagenesis.
In the current work, translocations affecting the IGH 
locus were encountered in DLBCL cases that harbored so-
matic mutations in NHEJ genes. NHEJ defects, in Trp53- 
deficient mice, strongly predispose to the development of 
pro–B cell lymphomas that harbor interchromosomal trans-
locations involving the IgH locus (Ferguson and Alt, 2001; 
Rooney et al., 2004). The role of C-NHEJ as a suppressor 
of interchromosomal translocations might relate to the fact 
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one of the major cancer drug research focuses and requires 
the comprehensive characterization of DNA repair defects 
in tumors (Curtin, 2012). Our work has provided a basis for 
developing similar therapeutic strategies for DLBCLs. The 
impact of mutations in DNA repair genes on response to 
treatment and patient prognosis should be further assessed in 
larger cohorts of patients.
MATERIALS AND METHODS
Patient materials. DNA was extracted from 29 mature B cell lymphoma 
frozen biopsies and the respective paired blood samples, collected at Sun 
Yat-Sen University Cancer Center (Guangzhou, China), to undergo targeted 
next-generation sequencing of DNA repair genes. This collection included 
22 DLBCL, of which 19 were primary and 3 relapsed (derived from different 
patients), 5 primary FL, and 2 primary BL, all derived from Chinese patients. 
None of the patients underwent chemotherapy before biopsy collection, except 
for the relapsed cases where patients had been treated with R-CHOP. The 
median age of the DLBCL patients at diagnosis was 65 yr, and the cohort 
comprised 13 females and 9 males. Seven DLBCL samples were classified as 
germinal center B cell–like (GCB), whereas 15 DLBCL samples were classified 
as non-GCB, according to the Hans algorithm (Hans et al., 2004). The tumor 
content of the DLBCL tumors was estimated to be at least 80% in all cases by 
histological evaluation. DNA was also extracted from frozen biopsies from an 
additional 250 DLBCL, collected in biobanks at Uppsala’s University Hospital 
(171 DLBCL from Swedish patients) and Sun Yat-Sen University Cancer 
Center (79 DLBCL from Chinese patients) for cohort expansion studies. 
10 additional paired blood samples were available for the extended cohort of 
Chinese DLBCL. Furthermore, DNA isolated from the peripheral blood 
from 67 Chinese DLBCL patients and 429 Chinese and 1,030 Swedish blood 
donors was used for assessing population frequencies of a selected set of 
genetic variants. DNA processed by Selector technology and SOLiD sequenc-
ing was isolated by the DNeasy Tissue and Blood kit (QIAGEN), according 
to the manufacturer’s instructions. DNA from subsets of samples composing 
the expanded cohort was extracted by different methodologies. RNA was 
extracted from 61 DLBCL cases and 8 normal lymph nodes with Trizol re-
agent (Life Technologies), according to the manufacturer’s instructions. The 
institutional review boards at the Sun Yat-Sen University Cancer Center and 
Uppsala University approved the study.
Target enrichment and high-throughput sequencing of DNA-repair 
genes. 58 genomic DNAs were enriched for the coding regions of 73 DNA 
repair genes, as well as TNFAIP3, a known DLBCL tumor suppressor (Table S1). 
The Selector method (an earlier version of the current HaloPlex from Agilent) 
was applied in the enrichment step (Johansson et al., 2011). It makes use of 
biotin-labeled Selector probes designed to contain two sequences comple-
mentary to both ends of a DNA target. Upon hybridization, probe binding 
induces circularization of target sequences that can be amplified selectively. 
800 ng of genomic DNA was fragmented through a combination of eight 
different restriction enzymatic reactions (100 ng of DNA each). After probe 
hybridization and circularization of the target sequences, this complex was 
separated from nontarget DNA by making use of streptavidin magnetic 
beads. After ligation of the circularized DNA molecules, specific amplification 
of the target sequences was achieved by a multiple displacement amplification 
reaction performed by a Phi29 DNA polymerase (TempliPhi; GE Healthcare).
To amplify the 1,158 exons that constituted the ROI, two different Se-
lector designs were attempted. Target nucleotides were covered by more than 
one selector probe to minimize the risk of hybridization failure provoked by 
nucleotide variations. In design 1, each targeted base was covered on average 
by 2.2 selector amplicons, whereas design 2 produced shorter fragments and 
allowed targeted bases to be covered on average by 3.3 selector amplicons 
(Table S2). Noncovered sequences in the ROI were mostly composed of 
repeat regions as identified by the RepeatMasker database (http://www 
.repeatmasker.org). In design 2, repetitive sequences were further avoided to 
improve sequencing efficiency at the cost of a slight reduction in the coverage 
Several clinical trials, which include B cell lymphoma pa-
tients, are currently ongoing to test the efficacy of PARP 
inhibitors as therapeutic agents (Kummar et al., 2011). The 
finding that a subset of DLBCL samples presents potentially 
loss-of-function mutations in PARP1, and/or lower expres-
sion levels of this gene supports the stratification of patients 
before the application of PARP-targeted therapies.
In addition to somatic mutations, several novel germline 
mutations were encountered in different DNA repair path-
ways, and we propose that the affected genes, especially the 
MMR genes, are good candidates for cancer susceptibility 
genes in mature B cell lymphomas. Heterozygous carriers of 
pathogenic mutations in certain MMR genes are strongly 
predisposed to colorectal but also to a variety of extracolonic 
neoplasias (Peltomäki, 2005). Although lymphomas are cur-
rently not considered to be part of the Lynch syndrome cancer 
spectrum, patients with biallelic mutations in certain MMR 
genes are predisposed to lymphomas and were sometimes 
shown to carry CSR defects (Wimmer and Etzler, 2008). Ad-
ditionally, murine models carrying germline inactivation of 
MMR genes are strongly predisposed to the development of 
both B and T cell lymphomas (de Wind et al., 1995; Edelmann 
et al., 1997; Qin et al., 1999). Screening of germline variations 
in a larger cohort of patients and functional characterization 
of these variants will be required to support our hypothesis.
Deregulation of proto-oncogene expression through mu-
tation or translocation of the BCL6, BCL2, or MYC genes, 
constitutional activation of the NF-B pathway through ge-
netic lesions in TNFAIP3, CARD11, CD79A/B, and MYD88 
genes, and epigenetic reprogramming, triggered by muta-
tions in genes such as MLL2, EZH2, MEF2B, and CREBBP, 
account for some of the most frequent events in DLBCL 
(Schneider et al., 2011). These alterations constitute cancer 
driver events, as they provide tumor cells with constitutive 
survival and proliferative signals, escape from apoptosis, and 
gene expression plasticity. Theoretically, as they all result from 
alterations at the DNA level, they might be a product of inef-
ficient DNA repair mechanisms in combination with an ex-
tremely high load of DNA damage in germinal center B cells, 
derived from high proliferation rates and from SHM and 
CSR processes. Previous next-generation sequencing studies 
on DLBCL have not focused on DNA repair genes, possibly 
because of the rare observation of recurrent mutations in 
genes other than TP53 (Morin et al., 2011; Pasqualucci et al., 
2011; Lohr et al., 2012; Zhang et al., 2013). We report here al-
terations in a variety of DNA repair genes in DLBCL tumors 
and provide evidence for a driver effect of alterations in the 
MMR and NHEJ pathways. Furthermore, most of the so-
matic mutations found derived from dominant tumor clones, 
suggesting that defects in DNA repair mechanisms are important 
and may constitute early driver events in lymphomagenesis.
As tumor cells acquire deficiencies in DNA repair path-
ways they may compensate such defects by relying on other 
pathways that display, at least partially, functional redundancy. 
The targeting of compensatory pathways by therapeutic in-
tervention, according to a principle of synthetic lethality, is 
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Molecularly barcoded 454 FLX Titanium (Roche) sequencing primers (Lib-A 
emPCR kit design), containing sequences complementary to the CS1 and 
CS2 primer tails, were added to the Access array together with 50 ng of each 
DNA sample (48 in total) so that all amplicons derived from the same DNA 
sample shared the same barcode. Indexed libraries were recovered for each 
sample in a single well of the Access array and analyzed with Agilent’s 2100 
Bioanalyzer (Agilent Technologies). Thereafter, samples were pooled and 
purified by gel extraction. After emulsion, PCR (Lib-A) samples were se-
quenced by the GS FLX+ System in a full PicoTiter Plate at Macrogen Inc. 
Analysis was performed with the GS Amplicon Variant Analyzer and poten-
tial variants validated by Sanger sequencing.
Population frequencies of single nucleotide variants. A proportion of 
the germline variants discovered by next-generation sequencing, together 
with all of the CHEK2 variants, were genotyped in Swedish and Chinese 
control samples using matrix-assisted laser desorption/ionization time of 
flight mass spectrometry (MALDI-TOF; Sequenom Inc.) as previously de-
scribed (Jurinke et al., 2002). PCR assays and associated extension reactions 
were designed using the MassArray assay design 3.1 software (Sequenom 
Inc.). Primers were acquired from Metabion GmbH (Planegg-Martinsried). 
The extension products were analyzed by the MassArray Compact MALDI-
TOF mass spectrometer (Sequenom Inc.). The MassARRAY Typer 4.0 soft-
ware (Sequenom Inc.) was used to analyze the resulting mass spectra for peak 
identification. Two independent scorers confirmed all genotypes. For the 
c.1100delC, p.H371Y and p.D438Y CHEK2 variants control typing was 
performed with Sanger sequencing because of the inability to produce a 
specific assay for MALDI-TOF. As the population-specific MAFs determined 
by typing were highly concordant with the ones derived from the 1000 
Genomes (http://www.1000genomes.org/) sequencing data, the latter were 
subsequently used for determining the MAFs of all germline variants discov-
ered by next generation sequencing. MAFs were extracted from 1000 
Genomes with the aid of VCFtools (Danecek et al., 2011).
Allelic imbalance and MSI analysis. Polymorphic sequence-tagged site 
(STS) markers were used to determine the zygosity status of the EXO1, 
MDC1, PARP1, RPA1, and TP53BP1 loci. STS markers and respective 
primer sequences were retrieved from the UCSC genome browser (http://
genome.ucsc.edu/) or the Ensembl genome browser (http://www.ensembl 
.org/) and, when necessary, primers were redesigned with Primer 3. The 
mononucleotide microsatellite markers BAT-25 and BAT-26 and the dinu-
cleotide markers D2S123 and D10S197 were used for the detection of MSI. 
Forward primers were fluorescently labeled with 6-carboxyfluorescein (6-FAM) 
at their 5-end and purified by HPLC. PCR reactions were run in a total of 
15 µl, containing 0.5 U GoTaqDNA polymerase (Promega), 0.66 µM of each 
primer, 330 µM dNTPs, 10 ng DNA, and 1.5 mM MgCl2. PCR products 
were diluted appropriately and mixed in a formamide solution containing 
GeneScan 500 LIZ Size Standard (Applied Biosystems). Thereafter, samples 
were loaded in a 48-capillary 3730 DNA Analyzer and analyzed with Peak 
Scanner software version 1.0 (Applied Biosystems). For the MSH2-mutated 
samples, MSI testing was also performed using a commercial kit (Microsatellite 
Instability Multiplex System kit; Promega) according to the manufacturer’s 
instructions. In brief, genomic DNA prepared from tumor tissue was ampli-
fied by PCR in a multiplex PCR, amplifying the selected microsatellite 
markers. Microsatellite analysis was performed using an ABI3500xl (Applied 
Biosystems) with the GeneMapper 4.1 software (Applied Biosystems).
Gene expression analysis. The relative expression of the EXO1, MDC1, 
PARP1, RPA1, and TP53BP1 genes was assessed by quantitative real time PCR 
(qPCR). Furthermore, the expression levels of the housekeeping genes ACTB, 
GAPDH, and HRPT1 were determined to perform inter-sample normalization. 
Intron-spanning assays were designed with Primer 3. RNAs were processed 
with the first-strand cDNA synthesis kit (GE Healthcare) and 10-µl reactions 
were prepared with the KAPA SYBR FAST ABI Prism qPCR reagent (Kapa 
Biosystems). Samples and standard curves were run in duplicate in a 7500 Fast 
Real-Time PCR System (Applied Biosystems). Analysis was performed with the 
7500 System SDS Software, version 1.4 (Applied Biosystems).
of the ROI (Table S2). Five DLBCL and respective normal pairs were en-
riched by design 1, and the remaining samples were enriched by design 2. 
Success of enrichment of target sequences was monitored by quantitative 
PCR to measure the relative levels of several on- and off-target amplicons.
300 ng of each enrichment product was fragmented using the Covaris 
S2 system, after which the standard library construction kit for SOLiD v3 
(Applied Biosystems), for design 1, and SOLiD v4, for design 2, were used to 
barcode and prepare the samples for sequencing. Barcoded samples were 
pooled and sequenced at the Uppsala Genome Center (Uppsala, Sweden). 
Samples from design 1 were sequenced in two separate runs, each making use 
of a quarter of a sequencing slide, whereas samples derived from design 2 were 
sequenced on three quarters of sequencing slide. The SOLiD libraries from 
16 samples from design 2 were further sequenced in an additional run to in-
crease coverage and depth. A HapMap sample NA19240 was subjected to the 
same enrichment (design 1) and sequencing procedures to evaluate the meth-
od’s specificity and reproducibility. Design of selector probes and sequence li-
brary preparation were performed at Halo Genomics (Uppsala, Sweden).
Analysis of SOLiD data. SOLiD short reads were aligned with 
MosaikAligner version 1.1.0018; -hs 15, -mm 6, -ms 6, -mhp 100, and -act 
20 (Mosaik; The MarthLab) against the human reference genome (hg18). 
Alignments from samples that were sequenced twice were merged using 
MosaikMerge. The combined alignments were then exported to SAM/BAM 
format and reanalyzed by in-house software to deal with artificial insertions/
deletions provoked by “forced” alignments. Single nucleotide variants (SNVs) 
and small insertions and deletions (indels) detection were performed with 
SNPmania (in-house software). Somatic alterations were determined by 
comparing the MAF between tumor and normal at specific base positions. 
A minimum of 10 and 5 reads in either normal and tumor samples was re-
quired as well as the representation of the minor allele by at least 5% of the 
reads in the tumor sample. Additionally, variant detection against the human 
reference genome (hg18) was also performed by flagging base positions in 
which the reference allele was represented at a frequency of 0–0.8 in posi-
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(Roche) according to the manufacturer’s instructions. Specific primers con-
taining universal tails (CS1 and CS2) were designed to produce ampli-
cons between 300 and 350 bp at the coding regions of the genes of interest. 
 o
n
 M
arch 12, 2014
jem.rupress.org
D
ow
nloaded from
 
Published August 19, 2013
1740 DNA repair gene defects in DLBCL | de Miranda et al.
Ahn, J., M. Urist, and C. Prives. 2004. The Chk2 protein kinase. DNA Repair 
(Amst.). 3:1039–1047. http://dx.doi.org/10.1016/j.dnarep.2004.03.033
Antoni, L., N. Sodha, I. Collins, and M.D. Garrett. 2007. CHK2 kinase: 
cancer susceptibility and cancer therapy - two sides of the same coin? 
Nat. Rev. Cancer. 7:925–936. http://dx.doi.org/10.1038/nrc2251
Audebert, M., B. Salles, and P. Calsou. 2004. Involvement of poly(ADP- 
ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative 
route for DNA double-strand breaks rejoining. J. Biol. Chem. 279: 
55117–55126. http://dx.doi.org/10.1074/jbc.M404524200
Bardwell, P.D., C.J. Woo, K. Wei, Z. Li, A. Martin, S.Z. Sack, T. Parris, 
W. Edelmann, and M.D. Scharff. 2004. Altered somatic hypermutation 
and reduced class-switch recombination in exonuclease 1-mutant mice. 
Nat. Immunol. 5:224–229. http://dx.doi.org/10.1038/ni1031
Bell, D.W., S.H. Kim, A.K. Godwin, T.A. Schiripo, P.L. Harris, S.M. 
Haserlat, D.C. Wahrer, C.A. Haiman, M.B. Daly, K.B. Niendorf, et al. 
2007. Genetic and functional analysis of CHEK2 (CHK2) variants 
in multiethnic cohorts. Int. J. Cancer. 121:2661–2667. http://dx.doi 
.org/10.1002/ijc.23026
Boboila, C., M. Jankovic, C.T. Yan, J.H. Wang, D.R. Wesemann, T. Zhang, A. 
Fazeli, L. Feldman, A. Nussenzweig, M. Nussenzweig, and F.W. Alt. 2010. 
Alternative end-joining catalyzes robust IgH locus deletions and translo-
cations in the combined absence of ligase 4 and Ku70. Proc. Natl. Acad. Sci. 
USA. 107:3034–3039. http://dx.doi.org/10.1073/pnas.0915067107
Boboila, C., F.W. Alt, and B. Schwer. 2012. Classical and alternative end-
joining pathways for repair of lymphocyte-specific and general DNA 
double-strand breaks. Adv. Immunol. 116:1–49. http://dx.doi.org/ 
10.1016/B978-0-12-394300-2.00001-6
Bryant, H.E., N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, 
S. Kyle, M. Meuth, N.J. Curtin, and T. Helleday. 2005. Specific killing 
of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) poly-
merase. Nature. 434:913–917. http://dx.doi.org/10.1038/nature03443
Cancer Genome Atlas Network. 2012. Comprehensive molecular char-
acterization of human colon and rectal cancer. Nature. 487:330–337. 
http://dx.doi.org/10.1038/nature11252
Compagno, M., W.K. Lim, A. Grunn, S.V. Nandula, M. Brahmachary, 
Q. Shen, F. Bertoni, M. Ponzoni, M. Scandurra, A. Califano, et al. 
2009. Mutations of multiple genes cause deregulation of NF-kappaB 
in diffuse large B-cell lymphoma. Nature. 459:717–721. http://dx.doi 
.org/10.1038/nature07968
Curtin, N.J. 2012. DNA repair dysregulation from cancer driver to therapeu-
tic target. Nat. Rev. Cancer. 12:801–817. http://dx.doi.org/10.1038/ 
nrc3399
Danecek, P., A. Auton, G. Abecasis, C.A. Albers, E. Banks, M.A. DePristo, 
R.E. Handsaker, G. Lunter, G.T. Marth, S.T. Sherry, et al; 1000 
Genomes Project Analysis Group. 2011. The variant call format and 
VCFtools. Bioinformatics. 27:2156–2158. http://dx.doi.org/10.1093/ 
bioinformatics/btr330
de Miranda, N.F., A. Björkman, and Q. Pan-Hammarström. 2011. DNA repair: 
the link between primary immunodeficiency and cancer. Ann. N.Y. Acad. 
Sci. 1246:50–63. http://dx.doi.org/10.1111/j.1749-6632.2011.06322.x
de Wind, N., M. Dekker, A. Berns, M. Radman, and H. te Riele. 1995. 
Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, 
methylation tolerance, hyperrecombination, and predisposition to cancer. 
Cell. 82:321–330. http://dx.doi.org/10.1016/0092-8674(95)90319-4
DePristo, M.A., E. Banks, R. Poplin, K.V. Garimella, J.R. Maguire, C. Hartl, 
A.A. Philippakis, G. del Angel, M.A. Rivas, M. Hanna, et al. 2011. A 
framework for variation discovery and genotyping using next-generation 
DNA sequencing data. Nat. Genet. 43:491–498. http://dx.doi.org/10 
.1038/ng.806
Di Noia, J.M., and M.S. Neuberger. 2007. Molecular mechanisms of anti-
body somatic hypermutation. Annu. Rev. Biochem. 76:1–22. http://dx 
.doi.org/10.1146/annurev.biochem.76.061705.090740
Du, L., R. Peng, A. Björkman, N. Filipe de Miranda, C. Rosner, A. Kotnis, 
M. Berglund, C. Liu, R. Rosenquist, G. Enblad, et al. 2012. Cernunnos 
influences human immunoglobulin class switch recombination and may 
be associated with B cell lymphomagenesis. J. Exp. Med. 209:291–305. 
http://dx.doi.org/10.1084/jem.20110325
Edelmann, W., K. Yang, A. Umar, J. Heyer, K. Lau, K. Fan, W. Liedtke, 
P.E. Cohen, M.F. Kane, J.R. Lipford, et al. 1997. Mutation in the 
Exome sequencing. Exome sequencing was performed in 19 DLBCL tu-
mors, including 17 tumors that underwent targeted sequencing of DNA re-
pair genes and 2 additional tumors that displayed MSI. In brief, genomic 
DNA was processed into fragments between 150 and 200 bp and Illumina 
sequencing adapters were ligated to both ends of the resulting fragments. The 
adapter-ligated templates were purified by AgencourtAMPure SPRI beads 
(Beckman Coulter) and fragments with insert size of 200 bp were excised. 
Extracted DNA was amplified by ligation-mediated polymerase chain reac-
tion (LM-PCR), purified, and hybridized to the SureSelectBiotinylated 
RNA Library (BAITS; Agilent Technologies) for enrichment. Hybridized 
fragments were bound to streptavidin beads, whereas nonhybridized frag-
ments were washed out after 24 h of incubation. Captured LM-PCR prod-
ucts were then subjected to the 2100 Bioanalyzer (Agilent) to estimate the 
magnitude of enrichment. Each captured library was loaded on a Hiseq2000 
platform (Illumina), and high-throughput sequencing was performed for 
each captured library independently to ensure that each sample met the de-
sired mean fold coverage (>50×). Raw image files were processed by base 
calling software (1.7; Illumina) for base calling with default parameters and 
the sequences of each individual were generated as 90-bp paired-end reads. 
During bioinformatic analysis, the adapter sequences in the raw data were 
removed, and low-quality reads were discarded. Sequences were aligned 
to the genome with Burrows-Wheeler Aligner (BWA) from which BAM 
files were obtained (Li and Durbin, 2009). Somatic indels were detected 
with GATK (Li et al., 2009b), whereas SNVs were detected using Varscan 
(Koboldt et al., 2009). All variants underwent visual inspection. Sequencing 
and data analysis was performed at BGI (Shenzhen, China).
Detection of chromosomal translocations by FISH. Vysis LSI IGH/
BCL2 dual-color, dual-fusion translocation probe, Vysis LSI BCL6 dual-
color, break-apart rearrangement probe, Vysis LSI MYC dual-color, break-
apart rearrangement probe, and Vysis LSI IGH break-apart rearrangement 
probe were purchased from Abbott Molecular Inc. Sample processing and 
hybridization were performed according to the manufacturer’s instruction 
and, as described previously, (Ribeiro et al., 2006). Slides were counterstained 
with DAPI (Vector Laboratories), and fluorescent images were sequentially 
captured with a Cohu 4900 charge-coupled device camera coupled to an 
Axioplan fluorescence microscope (Carl Zeiss).
Statistical analysis. Statistical tests and graph construction was performed 
with Prism (version 4.00; GraphPad Software).
Online supplemental material. Table S1 shows the genes sequenced 
by Selector and SOLiD. Table S2 summarizes the Selector capture and 
SOLiD sequencing performances. Table S3 shows all somatic and germ-
line (novel and rare) mutations identified by Selector/SOLiD sequencing. 
Fig. S1 summarizes the SNV detection process from the Selector/SOLiD 
sequencing data. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20122842/DC1.
We thank Dr. K. Duvefelt for help in genotyping, R. Vossen for assistance with 
the Fluidigm technology, and Prof. L. Hammarström for critical reading of the 
manuscript.
This work was supported by the Swedish Cancer Society, the Swedish Research 
Council, the European Research Council (242551-ImmunoSwitch), and the KIDS 
program at the Karolinska Institutet.
The authors have no conflicting financial interests.
Submitted: 24 December 2012
Accepted: 24 July 2013
REFERENCES
Adzhubei, I.A., S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. 
Bork, A.S. Kondrashov, and S.R. Sunyaev. 2010. A method and server 
for predicting damaging missense mutations. Nat. Methods. 7:248–249. 
http://dx.doi.org/10.1038/nmeth0410-248
 o
n
 M
arch 12, 2014
jem.rupress.org
D
ow
nloaded from
 
Published August 19, 2013
JEM Vol. 210, No. 9 
Article
1741
Li, H., and R. Durbin. 2009. Fast and accurate short read alignment with 
Burrows-Wheeler transform. Bioinformatics. 25:1754–1760. http://dx 
.doi.org/10.1093/bioinformatics/btp324
Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, 
G. Abecasis, and R. Durbin; 1000 Genome Project Data Processing 
Subgroup. 2009a. The Sequence Alignment/Map format and SAMtools. 
Bioinformatics. 25:2078–2079. http://dx.doi.org/10.1093/bioinformatics/ 
btp352
Li, R., Y. Li, X. Fang, H. Yang, J. Wang, K. Kristiansen, and J. Wang. 2009b. 
SNP detection for massively parallel whole-genome resequencing. Genome 
Res. 19:1124–1132. http://dx.doi.org/10.1101/gr.088013.108
Li, J., and D.F. Stern. 2005. Regulation of CHK2 by DNA-dependent protein 
kinase. J. Biol. Chem. 280:12041–12050. http://dx.doi.org/10.1074/jbc 
.M412445200
Lieber, M.R. 2010. The mechanism of double-strand DNA break repair by the 
nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 79:181–
211. http://dx.doi.org/10.1146/annurev.biochem.052308.093131
Liu, H.X., X.L. Zhou, T. Liu, B. Werelius, G. Lindmark, N. Dahl, and A. 
Lindblom. 2003. The role of hMLH3 in familial colorectal cancer. Cancer 
Res. 63:1894–1899.
Liu, M., J.L. Duke, D.J. Richter, C.G. Vinuesa, C.C. Goodnow, S.H. 
Kleinstein, and D.G. Schatz. 2008. Two levels of protection for the 
B cell genome during somatic hypermutation. Nature. 451:841–845. 
http://dx.doi.org/10.1038/nature06547
Lohr, J.G., P. Stojanov, M.S. Lawrence, D. Auclair, B. Chapuy, C. Sougnez, 
P. Cruz-Gordillo, B. Knoechel, Y.W. Asmann, S.L. Slager, et al. 2012. 
Discovery and prioritization of somatic mutations in diffuse large B-cell 
lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. 
USA. 109:3879–3884. http://dx.doi.org/10.1073/pnas.1121343109
Martin, A., Z. Li, D.P. Lin, P.D. Bardwell, M.D. Iglesias-Ussel, W. Edelmann, 
and M.D. Scharff. 2003. Msh2 ATPase activity is essential for somatic hy-
permutation at a-T basepairs and for efficient class switch recombination. 
J. Exp. Med. 198:1171–1178. http://dx.doi.org/10.1084/jem.20030880
Martomo, S.A., W.W. Yang, and P.J. Gearhart. 2004. A role for Msh6 but 
not Msh3 in somatic hypermutation and class switch recombination. 
J. Exp. Med. 200:61–68. http://dx.doi.org/10.1084/jem.20040691
Morin, R.D., M. Mendez-Lago, A.J. Mungall, R. Goya, K.L. Mungall, R.D. 
Corbett, N.A. Johnson, T.M. Severson, R. Chiu, M. Field, et al. 2011. 
Frequent mutation of histone-modifying genes in non-Hodgkin lym-
phoma. Nature. 476:298–303. http://dx.doi.org/10.1038/nature10351
Nagarajan, N., D. Bertrand, A.M. Hillmer, Z.J. Zang, F. Yao, P.E. Jacques, 
A.S. Teo, I. Cutcutache, Z. Zhang, W.H. Lee, et al. 2012. Whole- 
genome reconstruction and mutational signatures in gastric cancer. Genome 
Biol. 13:R115. http://dx.doi.org/10.1186/gb-2012-13-12-r115
Pasqualucci, L., P. Neumeister, T. Goossens, G. Nanjangud, R.S. Chaganti, 
R. Küppers, and R. Dalla-Favera. 2001. Hypermutation of mul-
tiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 
412:341–346. http://dx.doi.org/10.1038/35085588
Pasqualucci, L., G. Bhagat, M. Jankovic, M. Compagno, P. Smith, M. Muramatsu, 
T. Honjo, H.C. Morse III, M.C. Nussenzweig, and R. Dalla-Favera. 2008. 
AID is required for germinal center-derived lymphomagenesis. Nat. 
Genet. 40:108–112. http://dx.doi.org/10.1038/ng.2007.35
Pasqualucci, L., V. Trifonov, G. Fabbri, J. Ma, D. Rossi, A. Chiarenza, V.A. 
Wells, A. Grunn, M. Messina, O. Elliot, et al. 2011. Analysis of the cod-
ing genome of diffuse large B-cell lymphoma. Nat. Genet. 43:830–837. 
http://dx.doi.org/10.1038/ng.892
Peltomäki, P. 2005. Lynch syndrome genes. Fam. Cancer. 4:227–232. http://
dx.doi.org/10.1007/s10689-004-7993-0
Qin, X., L. Liu, and S.L. Gerson. 1999. Mice defective in the DNA mismatch 
gene PMS2 are hypersensitive to MNU induced thymic lymphoma 
and are partially protected by transgenic expression of human MGMT. 
Oncogene. 18:4394–4400. http://dx.doi.org/10.1038/sj.onc.1202798
Ramiro, A.R., M. Jankovic, T. Eisenreich, S. Difilippantonio, S. Chen-Kiang, 
M. Muramatsu, T. Honjo, A. Nussenzweig, and M.C. Nussenzweig. 2004. 
AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 
118:431–438. http://dx.doi.org/10.1016/j.cell.2004.08.006
Ribeiro, F.R., C. Jerónimo, R. Henrique, D. Fonseca, J. Oliveira, R.A. Lothe, and 
M.R. Teixeira. 2006. 8q gain is an independent predictor of poor survival 
mismatch repair gene Msh6 causes cancer susceptibility. Cell. 91:467–
477. http://dx.doi.org/10.1016/S0092-8674(00)80433-X
Falck, J., N. Mailand, R.G. Syljuåsen, J. Bartek, and J. Lukas. 2001. The 
ATM-Chk2-Cdc25A checkpoint pathway guards against radioresis-
tant DNA synthesis. Nature. 410:842–847. http://dx.doi.org/10.1038/ 
35071124
Ferguson, D.O., and F.W. Alt. 2001. DNA double strand break repair and 
chromosomal translocation: lessons from animal models. Oncogene. 
20:5572–5579. http://dx.doi.org/10.1038/sj.onc.1204767
Guidi, C.J., T.M. Veal, S.N. Jones, and A.N. Imbalzano. 2004. Transcriptional 
compensation for loss of an allele of the Ini1 tumor suppressor. J. Biol. 
Chem. 279:4180–4185. http://dx.doi.org/10.1074/jbc.M312043200
Hans, C.P., D.D. Weisenburger, T.C. Greiner, R.D. Gascoyne, J. Delabie, G. 
Ott, H.K. Müller-Hermelink, E. Campo, R.M. Braziel, E.S. Jaffe, et al. 
2004. Confirmation of the molecular classification of diffuse large B-cell 
lymphoma by immunohistochemistry using a tissue microarray. Blood. 
103:275–282. http://dx.doi.org/10.1182/blood-2003-05-1545
Hicks, S., D.A. Wheeler, S.E. Plon, and M. Kimmel. 2011. Prediction of mis-
sense mutation functionality depends on both the algorithm and sequence 
alignment employed. Hum. Mutat. 32:661–668. http://dx.doi.org/10 
.1002/humu.21490
Homer, N., B. Merriman, and S.F. Nelson. 2009. BFAST: an alignment 
tool for large scale genome resequencing. PLoS ONE. 4:e7767. http://
dx.doi.org/10.1371/journal.pone.0007767
Jiricny, J. 2006. The multifaceted mismatch-repair system. Nat. Rev. Mol. 
Cell Biol. 7:335–346. http://dx.doi.org/10.1038/nrm1907
Johansson, H., M. Isaksson, E.F. Sörqvist, F. Roos, J. Stenberg, T. Sjöblom, 
J. Botling, P. Micke, K. Edlund, S. Fredriksson, et al. 2011. Targeted 
resequencing of candidate genes using selector probes. Nucleic Acids Res. 
39:e8. http://dx.doi.org/10.1093/nar/gkq1005
Jung, D., C. Giallourakis, R. Mostoslavsky, and F.W. Alt. 2006. Mechanism 
and control of V(D)J recombination at the immunoglobulin heavy chain 
locus. Annu. Rev. Immunol. 24:541–570. http://dx.doi.org/10.1146/
annurev.immunol.23.021704.115830
Jurinke, C., D. van den Boom, C.R. Cantor, and H. Köster. 2002. 
Automated genotyping using the DNA MassArray technology. Methods 
Mol. Biol. 187:179–192.
Klein, U., and R. Dalla-Favera. 2008. Germinal centres: role in B-cell physi-
ology and malignancy. Nat. Rev. Immunol. 8:22–33. http://dx.doi.org/ 
10.1038/nri2217
Koboldt, D.C., K. Chen, T. Wylie, D.E. Larson, M.D. McLellan, E.R. 
Mardis, G.M. Weinstock, R.K. Wilson, and L. Ding. 2009. VarScan: 
variant detection in massively parallel sequencing of individual and 
pooled samples. Bioinformatics. 25:2283–2285. http://dx.doi.org/10.1093/ 
bioinformatics/btp373
Kotnis, A., L. Du, C. Liu, S.W. Popov, and Q. Pan-Hammarström. 2009. Non-
homologous end joining in class switch recombination: the beginning 
of the end. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364:653–665. http://
dx.doi.org/10.1098/rstb.2008.0196
Krishnakumar, R., and W.L. Kraus. 2010. The PARP side of the nucleus: 
molecular actions, physiological outcomes, and clinical targets. Mol. Cell. 
39:8–24. http://dx.doi.org/10.1016/j.molcel.2010.06.017
Kumar, P., S. Henikoff, and P.C. Ng. 2009. Predicting the effects of coding 
non-synonymous variants on protein function using the SIFT algorithm. 
Nat. Protoc. 4:1073–1081. http://dx.doi.org/10.1038/nprot.2009.86
Kummar, S., A. Chen, J. Ji, Y. Zhang, J.M. Reid, M. Ames, L. Jia, M. Weil, 
G. Speranza, A.J. Murgo, et al. 2011. Phase I study of PARP inhibitor 
ABT-888 in combination with topotecan in adults with refractory solid 
tumors and lymphomas. Cancer Res. 71:5626–5634. http://dx.doi.org/ 
10.1158/0008-5472.CAN-11-1227
Küppers, R., and R. Dalla-Favera. 2001. Mechanisms of chromosomal translo-
cations in B cell lymphomas. Oncogene. 20:5580–5594. http://dx.doi.org/ 
10.1038/sj.onc.1204640
Lenz, G., I. Nagel, R. Siebert, A.V. Roschke, W. Sanger, G.W. Wright, S.S. 
Dave, B. Tan, H. Zhao, A. Rosenwald, et al. 2007. Aberrant immunoglob-
ulin class switch recombination and switch translocations in activated 
B cell–like diffuse large B cell lymphoma. J. Exp. Med. 204:633–643. 
http://dx.doi.org/10.1084/jem.20062041
 o
n
 M
arch 12, 2014
jem.rupress.org
D
ow
nloaded from
 
Published August 19, 2013
1742 DNA repair gene defects in DLBCL | de Miranda et al.
in diagnostic needle biopsies from prostate cancer suspects. Clin. Cancer 
Res. 12:3961–3970. http://dx.doi.org/10.1158/1078-0432.CCR-05- 
1977
Robert, I., F. Dantzer, and B. Reina-San-Martin. 2009. Parp1 facilitates 
alternative NHEJ, whereas Parp2 suppresses IgH/c-myc transloca-
tions during immunoglobulin class switch recombination. J. Exp. Med. 
206:1047–1056. http://dx.doi.org/10.1084/jem.20082468
Robinson, J.T., H. Thorvaldsdóttir, W. Winckler, M. Guttman, E.S. 
Lander, G. Getz, and J.P. Mesirov. 2011. Integrative genomics viewer. 
Nat. Biotechnol. 29:24–26. http://dx.doi.org/10.1038/nbt.1754
Rooney, S., J. Sekiguchi, S. Whitlow, M. Eckersdorff, J.P. Manis, C. Lee, 
D.O. Ferguson, and F.W. Alt. 2004. Artemis and p53 cooperate to 
suppress oncogenic N-myc amplification in progenitor B cells. Proc. 
Natl. Acad. Sci. USA. 101:2410–2415. http://dx.doi.org/10.1073/pnas 
.0308757101
Schneider, C., L. Pasqualucci, and R. Dalla-Favera. 2011. Molecular patho-
genesis of diffuse large B-cell lymphoma. Semin. Diagn. Pathol. 28:167–
177. http://dx.doi.org/10.1053/j.semdp.2011.04.001
Sodha, N., T.S. Mantoni, S.V. Tavtigian, R. Eeles, and M.D. Garrett. 
2006. Rare germ line CHEK2 variants identified in breast cancer families 
encode proteins that show impaired activation. Cancer Res. 66:8966–
8970. http://dx.doi.org/10.1158/0008-5472.CAN-06-1990
Stavnezer, J., A. Björkman, L. Du, A. Cagigi, and Q. Pan-Hammarström. 2010. 
Mapping of switch recombination junctions, a tool for studying DNA 
repair pathways during immunoglobulin class switching. Adv. Immunol. 
108:45–109. http://dx.doi.org/10.1016/B978-0-12-380995-7.00003-3
Wimmer, K., and J. Etzler. 2008. Constitutional mismatch repair-deficiency 
syndrome: have we so far seen only the tip of an iceberg? Hum. Genet. 
124:105–122. http://dx.doi.org/10.1007/s00439-008-0542-4
Zhang, J., V. Grubor, C.L. Love, A. Banerjee, K.L. Richards, P.A. Mieczkowski, 
C. Dunphy, W. Choi, W.Y. Au, G. Srivastava, et al. 2013. Genetic het-
erogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA. 
110:1398–1403. http://dx.doi.org/10.1073/pnas.1205299110
Zhang, S., R. Lloyd, G. Bowden, B.W. Glickman, and J.G. de Boer. 2001. 
Msh2 DNA mismatch repair gene deficiency and the food-borne muta-
gen 2-amino-1-methy1-6-phenolimidazo [4,5-b] pyridine (PhIP) syner-
gistically affect mutagenesis in mouse colon. Oncogene. 20:6066–6072.
Zhao, J. and M.E. Winkler. 2000. Reduction of GC --> TA transversion 
mutation by overexpression of MutS in Escherichia coli K-12. J. Bacteriol. 
182:5025–5028. http://dx.doi.org/JB.182.17.5025-5028.2000
 o
n
 M
arch 12, 2014
jem.rupress.org
D
ow
nloaded from
 
Published August 19, 2013
